In 114 children aged 3–17 with achondroplasia, once-daily oral infigratinib for 52 weeks increased annualised height velocity versus placebo (difference 1.74 cm/year; P<0.001). Upper-to-lower body segment ratio did not differ; serious adverse events 5% vs 3%.
RCTn = 114
Savarirayan et al. Phase 3 Trial of Oral Infigratinib in Children with Achondroplasia